Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | DHFR | P00374 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | STARD3 | Q14849 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28342305 | 0.88 | TDP1 (0.42) | RAB9AMEN1KMT2ANPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL20492781 | 0.87 | ALDH1A1 (0.43) | RAB9AMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL6291722 | 0.81 | GRIN2B (0.55) | RAB9AMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6296037 | 0.81 | DRD4 (0.54) | RAB9AALDH1A1MAPTPKMMAPK1 | |
| SCHEMBL20492672 | 0.81 | MEN1 (0.48) | MEN1KMT2AALDH1A1MAPTL3MBTL1 | |
| SCHEMBL21063758 | 0.81 | ALDH1A1 (0.46) | MEN1KMT2AALDH1A1MAPTL3MBTL1 | |
| SCHEMBL6771430 | 0.81 | ALDH1A1 (0.42) | RAB9AMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL20492552 | 0.80 | DRD2 (0.42) | RAB9AMEN1KMT2ANPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL8186681 | 0.80 | GRIN2B (0.54) | RAB9AALDH1A1MAPTNPBWR1MCHR1 | |
| SCHEMBL28169331 | 0.79 | MEN1 (0.61) | RAB9AMEN1KMT2ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786305-B2 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786305-B2 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7230008-B2 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK & CO, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7230008-B2 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK & CO, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-6777426-B2 | SELECTIVE AGONISTS FOR HUMAN ALPHA 2 ADRENERGIC RECEPTORS; TREATING PAIN, MIGRAINE, HEADACHES, GLAUCOMA; 2-(INDAN-5-YL)AMINO-2-IMIDAZOLINE FOR EXAMPLE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-08-17 | — | — | US | disclosed |
| US-20020019390-A1 | Imidazole and imidazoline derivatives and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-02-14 | — | — | US | disclosed |
| US-6294566-B1 | ENANTIOMORPHS REVERSE AND ADRENERGIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-09-25 | — | — | US | disclosed |
| US-6245778-B1 | 1,6-naphthyridine anti-convulsants | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-06-12 | — | — | US | disclosed |
| US-6093727-A | A SELECTIVE AGONISTS FOR HUMAN ALPHA 2 RECEPTORS FOR TREATING DISORDERS AS HYPERTENSION, PAIN, GLAUCOMA, ALCOHOL AND DRUG WITHDRAWAL, ISCHEMIA, RHEUMATOID ARTHRITIS, MIGRAINE, COGNITIVE DEFICIENCY, SPASTICITY, DIARRHEA, NASAL CONGESTION | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-07-25 | — | — | US | disclosed |
| EP-1017694-A2 | N-5,6,7,8-TETRAHYDRO(1,6)NAPHTHYRIDINE-N'-PHENYLUREA DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2000-07-12 | — | — | EP | disclosed |
| EP-0986559-A1 | 1,6-NAPHTHYRIDINE ANTI-CONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-22 | — | — | EP | disclosed |
| WO-1999015526-A2 | N-5,6,7,8-TETRAHYDRO(1,6)NAPHTHYRIDINE-N'-PHENYLUREA DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1999-04-01 | — | — | WO | disclosed |
| US-5866579-A | SELECTIVE AGONISTS FOR CLONED HUMAN ALPHA-2 ADRENERGIC RECEPTORS. | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1998054184-A1 | 1,6-NAPHTHYRIDINE ANTI-CONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019390-A1 | Imidazole and imidazoline derivatives and uses thereof | ADRB2, ADRA2C, ADRB3 | RAB9A 2112/4885MEN1 3146/4885KMT2A 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.